101 related articles for article (PubMed ID: 29529279)
1. Nonclinical Safety Assessment of the γ-Secretase Inhibitor Avagacestat.
Simutis FJ; Sanderson TP; Pilcher GD; Graziano MJ
Toxicol Sci; 2018 Jun; 163(2):525-542. PubMed ID: 29529279
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.
Albright CF; Dockens RC; Meredith JE; Olson RE; Slemmon R; Lentz KA; Wang JS; Denton RR; Pilcher G; Rhyne PW; Raybon JJ; Barten DM; Burton C; Toyn JH; Sankaranarayanan S; Polson C; Guss V; White R; Simutis F; Sanderson T; Gillman KW; Starrett JE; Bronson J; Sverdlov O; Huang SP; Castaneda L; Feldman H; Coric V; Zaczek R; Macor JE; Houston J; Berman RM; Tong G
J Pharmacol Exp Ther; 2013 Mar; 344(3):686-95. PubMed ID: 23275065
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Tong G; Wang JS; Sverdlov O; Huang SP; Slemmon R; Croop R; Castaneda L; Gu H; Wong O; Li H; Berman RM; Smith C; Albright CF; Dockens RC
Clin Ther; 2012 Mar; 34(3):654-67. PubMed ID: 22381714
[TBL] [Abstract][Full Text] [Related]
4. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
5. Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men.
Tong G; Castaneda L; Wang JS; Sverdlov O; Huang SP; Slemmon R; Gu H; Wong O; Li H; Berman RM; Smith C; Albright C; Dockens RC
Clin Drug Investig; 2012 Nov; 32(11):761-9. PubMed ID: 23018285
[TBL] [Abstract][Full Text] [Related]
6. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Tong G; Wang JS; Sverdlov O; Huang SP; Slemmon R; Croop R; Castaneda L; Gu H; Wong O; Li H; Berman RM; Smith C; Albright CF; Dockens R
Br J Clin Pharmacol; 2013 Jan; 75(1):136-45. PubMed ID: 22616739
[TBL] [Abstract][Full Text] [Related]
7. Gamma secretase inhibition: Effects on fertility and embryo-fetal development in rats.
Sivaraman L; Sanderson T
Toxicol Appl Pharmacol; 2023 Jun; 469():116512. PubMed ID: 37030625
[TBL] [Abstract][Full Text] [Related]
8. A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects.
Dockens R; Wang JS; Castaneda L; Sverdlov O; Huang SP; Slemmon R; Gu H; Wong O; Li H; Berman RM; Smith C; Albright CF; Tong G
Clin Pharmacokinet; 2012 Oct; 51(10):681-93. PubMed ID: 23018531
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
[TBL] [Abstract][Full Text] [Related]
10. Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitors that selectively inhibit the production of amyloid-β over Notch.
Probst G; Aubele DL; Bowers S; Dressen D; Garofalo AW; Hom RK; Konradi AW; Marugg JL; Mattson MN; Neitzel ML; Semko CM; Sham HL; Smith J; Sun M; Truong AP; Ye XM; Xu YZ; Dappen MS; Jagodzinski JJ; Keim PS; Peterson B; Latimer LH; Quincy D; Wu J; Goldbach E; Ness DK; Quinn KP; Sauer JM; Wong K; Zhang H; Zmolek W; Brigham EF; Kholodenko D; Hu K; Kwong GT; Lee M; Liao A; Motter RN; Sacayon P; Santiago P; Willits C; Bard F; Bova MP; Hemphill SS; Nguyen L; Ruslim L; Tanaka K; Tanaka P; Wallace W; Yednock TA; Basi GS
J Med Chem; 2013 Jul; 56(13):5261-74. PubMed ID: 23713656
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h.
Hawkins J; Harrison DC; Ahmed S; Davis RP; Chapman T; Marshall I; Smith B; Mead TL; Medhurst A; Giblin GM; Hall A; Gonzalez MI; Richardson J; Hussain I
Neurodegener Dis; 2011; 8(6):455-64. PubMed ID: 21389687
[TBL] [Abstract][Full Text] [Related]
13. Investigations on the Relationship Between Ovarian, Endocrine, and Renal Findings in Nonclinical Safety Studies of the γ-Secretase Inhibitor Avagacestat.
Simutis FJ; Sanderson TP; Pilcher GD; Graziano MJ
Toxicol Sci; 2019 Sep; 171(1):98-116. PubMed ID: 31165171
[TBL] [Abstract][Full Text] [Related]
14. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
Best JD; Smith DW; Reilly MA; O'Donnell R; Lewis HD; Ellis S; Wilkie N; Rosahl TW; Laroque PA; Boussiquet-Leroux C; Churcher I; Atack JR; Harrison T; Shearman MS
J Pharmacol Exp Ther; 2007 Feb; 320(2):552-8. PubMed ID: 17099072
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological and Toxicological Properties of the Potent Oral
Wagner SL; Rynearson KD; Duddy SK; Zhang C; Nguyen PD; Becker A; Vo U; Masliah D; Monte L; Klee JB; Echmalian CM; Xia W; Quinti L; Johnson G; Lin JH; Kim DY; Mobley WC; Rissman RA; Tanzi RE
J Pharmacol Exp Ther; 2017 Jul; 362(1):31-44. PubMed ID: 28416568
[TBL] [Abstract][Full Text] [Related]
16. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
Massard C; Azaro A; Soria JC; Lassen U; Le Tourneau C; Sarker D; Smith C; Ohnmacht U; Oakley G; Patel BKR; Yuen ESM; Benhadji KA; Rodon J
Ann Oncol; 2018 Sep; 29(9):1911-1917. PubMed ID: 30060061
[TBL] [Abstract][Full Text] [Related]
17. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
Lu Y; Zhang L; Nolan CE; Becker SL; Atchison K; Robshaw AE; Pustilnik LR; Osgood SM; Miller EH; Stepan AF; Subramanyam C; Efremov I; Hallgren AJ; Riddell D
J Pharmacol Exp Ther; 2011 Dec; 339(3):922-34. PubMed ID: 21930801
[TBL] [Abstract][Full Text] [Related]
18. Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ-secretase modulators reduced amyloidogenic Aβ peptides in vivo.
Huang Y; Li T; Eatherton A; Mitchell WL; Rong N; Ye L; Yang XJ; Jin S; Ding Y; Zhang J; Li Y; Wu Y; Jin Y; Sang Y; Cheng Z; Browne ER; Harrison DC; Hussain I; Wan Z; Hall A; Lau LF; Matsuoka Y
Neuropharmacology; 2013 Jul; 70():278-86. PubMed ID: 23485401
[TBL] [Abstract][Full Text] [Related]
19. Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects.
Toyn JH; Boy KM; Raybon J; Meredith JE; Robertson AS; Guss V; Hoque N; Sweeney F; Zhuo X; Clarke W; Snow K; Denton RR; Zuev D; Thompson LA; Morrison J; Grace J; Berisha F; Furlong M; Wang JS; Lentz KA; Padmanabha R; Cook L; Wei C; Drexler DM; Macor JE; Albright CF; Gasior M; Olson RE; Hong Q; Soares HD; AbuTarif M; Ahlijanian MK
J Pharmacol Exp Ther; 2016 Jul; 358(1):125-37. PubMed ID: 27189974
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of γ-Secretase Leads to an Increase in Presenilin-1.
Sogorb-Esteve A; García-Ayllón MS; Llansola M; Felipo V; Blennow K; Sáez-Valero J
Mol Neurobiol; 2018 Jun; 55(6):5047-5058. PubMed ID: 28815510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
